Neovasc (Vancouver, British Columbia) reported top-line results for its COSIRA (Coronary Sinus Reducer for treatment of Refractory Angina) trial assessing the efficacy and safety of the Neovasc Reducer, a new percutaneous device for the treatment of refractory angina. The data shows that the Reducer achieved its primary endpoint, significantly improving the symptoms and functioning of patients disabled by previously untreatable refractory angina.